Rezdiffra is showing promise in compensated MASH cirrhosis. At #EASL, Madrigal shared 2-year data: 65% of patients with CSPH at baseline moved to lower-risk categories. Fibrosis markers, liver stiffness and portal pressure also improved. 🔗 pmlive.com/pharma_news/ma…

We've been included in Bloomberg UK & Founders Forum Group's 25 European companies to watch in 2025! Grateful to be highlighted for our work in advanced liver disease, alongside other innovative companies in genAI, auto vehicles, space & biotech.🚀 Full list➡️bloomberg.com/features/2025-…

In just 6 years, Jenna went from managing an autoimmune condition to liver failure. She got a transplant just in time – but many aren't as lucky. A powerful reminder of how fast liver disease can progress and how long the wait for transplant can be. 🔗 liverfoundation.org/about-your-liv…

Announcing Dr. Quin Wills as the new CEO of Ochre Bio 👏 As founder & former CSO, Quin has shaped our RNA therapy strategy from day one. He now leads Ochre into it's next phase: progressing new drug candidates toward the clinic. 🔗 ochre-bio.com/2025/06/30/dr-…

🎉 Huge congratulations to the Ochre team who completed Sunday’s Race for Life for Cancer Research UK! Support the team here👉 fundraise.cancerresearchuk.org/team/ochre-bio

Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO. 🔗 Full story: buff.ly/vaI83Wh .GSK Boehringer Ingelheim University of Oxford Cambridge University #BiotechNews #RNAtherapeutics #LiverDisease

AI is reshaping how we diagnose and treat disease. In Mail+, Lara Lewington explores this shift, featuring our work using machine learning and human liver data to develop RNA therapies for late-stage disease. Article 👉 dailymail.co.uk/health/article…

Liver therapies are undergoing their most significant disruption in decades. In The Times and The Sunday Times, @Quin_Wills discusses how metabolic drugs like Wegovy & Mounjaro are moving us from symptom control to targeted therapies. Read the full article: thetimes.com/comment/column…

The NHS 10-Year Plan signals a shift toward earlier intervention, genomics, & smarter care systems. It’s great to see a national strategy reflect the importance of understanding disease biology & using AI to build more efficient, data-rich systems.

4.5M US adults live with chronic liver disease, & transplant demand far outpaces donors. In a recent Mayo Clinic video, Dr. Bashar Aqel talks about the anxious waits for life-saving surgery that many patients face while their conditions deteriorate. 🎥 youtube.com/watch?v=WBlByZ…

We’ve moved to our new home at the Alexandria Center® for Life Science, NYC! It includes our liver ICU, the world’s largest lab for ex vivo perfusion of donor livers, where we’re validating RNA therapies for late-stage liver disease. 🔗 Announcement: ochre-bio.com/2025/07/21/bio…

Lovely to see our NYC Liver ICU featured in Hacking Humanity by Lara Lewington, a book based on how technology is shaping healthcare. 👀 Spot us on p112 Lara also visited our Oxford lab last year to record a BBC Click feature (catch us from 07:25) 👉 bbc.co.uk/iplayer/episod…

New Phase 2a results show efimosfermin alfa, an FGF21 analogue, reduced liver fat by ≥30% in 85% of patients with MASH, in 12 wks. It’s encouraging to see progress in building the MASH treatment toolkit. Read👉 physiciansweekly.com/hepatic-steato… Lancet study 👉 thelancet.com/journals/langa…

12 year old Albie is competing in his 3rd British Transplant Games after a life-saving liver transplant at age 8. His story is a reminder of the need for liver transplants and better treatment options for those living with serious liver disease. 🔗 bournemouthecho.co.uk/news/25320021.…

NIH will no longer fund studies that rely only on animal testing. New proposals must include human-relevant models (AI, in silico tools, or organ-on-chip systems), driven by evidence that 90% of drugs fail in humans despite success in animal models. 🔗 drugdiscoverytrends.com/nih-announces-…

We've recently welcomed three exceptional new members to Team Ochre! 👋 📊 Nicholas, Head of Finance 🏢 Penny Chown, Senior Executive Assistant 🧬 Sylvia Zohrabian, Scientist Welcome to #TeamOchre, we're glad to have you with us!

How liver cells talk to each other – & to immune cells – shapes how disease begins and progresses. A new Mayo Clinic review explores how single-cell & spatial omics are helping map these networks & uncover more effective therapeutic targets. Read more: nature.com/articles/s4142…

One donor liver saved both Rachel, 54, & 2-year-old Luna Rose through a rare split transplant. Stories like theirs are examples of why it's important to develop new therapies for liver disease: to offer more options before transplant is the only one. 🔗 utswmed.org/medblog/split-…